Latest Breaking News On - அலெக்சாண்டர் வாஸ் - Page 1 : comparemela.com
VectorY Raises €31 Million in Seed Financing to Develop Next-Generation Gene Therapies Aimed at Muscular and CNS Disorders
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
VectorY Raises €31M in Seed Funding
finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.
Feb 16 2021 Read 304 Times
Dr Gerard Short, MBBS has joined biotech VarmX, a company focusing on innovative approaches for the reversal of anticoagulation, as Chief Medical Officer (CMO). He will be responsible for overseeing the clinical development of the company’s pipeline, including progression of its lead product, VMX-C001, into clinical proof of concept and registrational studies.
With more than 20 years working with both big pharma and biotechs, Dr Short’s clinical development expertise has a particular focus on rare diseases and gene therapy for haematological disorders. He joins VarmX from Freeline Therapeutics, where he served for five years as SVP Clinical and Regulatory and later SVP Medical Science, establishing an in-house pharmacovigilance function and advancing gene therapy clinical programmes in haemophilia B and Fabry’s disease. During a decade at Genzyme, he led the Global Development Team treatment programmes targeting Pompe’s disease (phase 3) and acut